The European Medicines Agency (EMA) today revealed that, in 2024, it recommended 114 medicines for marketing authorization.
Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European ...
The European Commission granted an approval under exceptional circumstances to InflaRx’s immunosuppressant. The European ...
GlobalData on MSN1d
Acadia submits MAA to EMA for Rett syndrome therapyAcadia Pharmaceuticals has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for ...
The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the ...
These launches belong to what Oelrich called “must-win battles” at Bayer as Xarelto loss of exclusivity reaches “full swing” ...
(RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) Tuesday, announced the submission of a Marketing Authorization Application or MAA to the European Medicines Agency or EMA for its Trofinetide, targeting ...
Stockhead on MSN1d
Health Check: Biotech partnership eyes Euro market expansion for Rett syndrome drugNeuren's partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment ...
Azafaros B.V. today announced that its lead asset, nizubaglustat, has been granted orphan drug designation from regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback